MOVING CLOSER TO ZERO RISK OF SURGICAL SITE INFECTION (SSI)

  • Our 1st product candidate, D-PLEX100, is under developed for the prevention of SSIs. D-PLEX100 is a secure antibiotic drug reservoir based on PLEX technology for controlled, continuous release of doxycycline into the surgical site up to four weeks.
  • Our pipeline is focused on Innovative local medications to transform the surgical practice and improve patient outcomes.

(1) In December 2019, we initiated a potentially pivotal Phase 3 clinical trial of D-PLEX100 for the prevention of sternal SSIs after cardiac surgery and, subject to feedback from the FDA, we plan to continue development of D-PLEX100 for the prevention of SSIs in patients undergoing abdominal surgery. We intend to pursue a broad label for D-PLEX100 for the prevention of SSIs, the scope of which will depend on the clinical data generated from our potentially pivotal Phase 3 clinical trials and discussions with the FDA and the EMA.

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >